WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. The founder is Ge Li. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchConsumer Discretionary, Healthcare, Real Estate
Tech for Global, Globalization Footprints of the Established and the New
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM